Efficacy of Biphasic Insulin Aspart 30 in Subjects With Type 2 Diabetes Failing on OADs

NovoMix® 30 (Biphasic Insulin Aspart 70/30) Titrate-to-target: An Observational Study of the Efficacy of NovoMix® 30 in Subjects With Type 2 Diabetes Mellitus Not Achieving Glycaemic Targets on OADs

This trial is conducted in North America. The aim of this trial is to investigate the efficacy of biphasic insulin aspart 30 in subjects with type 2 diabetes not achieving glycaemic targets on OADs (oral anti-diabetic drugs).

Inclusion Criteria:

• Type 2 diabetes mellitus for at least 12 months
• HbA1c between 7.5-14.5% (inclusive) at screening
• Insulin naïve
• An antidiabetic regimen that has been stable for at least 3 months prior to screening
• An antidiabetic regimen that includes a minimum of 2 OADs

Exclusion Criteria:

• Use of any insulin preparations within the past 6 months
• Active proliferative retinopathy or maculopathy requiring treatment within 6 months prior to screening